Horizon Discovery CRISPR Screening Service for Primary Human T Cells

Horizon Discovery has extended its CRISPR Screening Service to include ex vivo T lymphocytes. Horizon has adapted its established CRISPRko (knockout) platform to screen human T lymphocytes, adding CRISPRko screens in ex vivo T lymphocytes to its established CRISPR screening formats – CRISPRko, CRISPRi (interference) and CRISPRa (activation) – in cancer cell lines. The service extension meets the requirements of immunology-based research in drug discovery, allowing for the identification of new gene targets in biologically and potentially therapeutically relevant settings, the firm said.